Analysis of the US Safety Data for Edaravone (Radicava(®)) From the Third Year After Launch

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease with no curative therapies. Edaravone (Radicava(®)) (Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan), approved in the United States (US) for ALS in adults in 2017, was shown in a clinical trial to sl...

Descripción completa

Detalles Bibliográficos
Autores principales: Genge, Angela, Brooks, Benjamin Rix, Oskarsson, Björn, Kalin, Alexander, Ji, Ming, Apple, Stephen, Bower, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433633/
https://www.ncbi.nlm.nih.gov/pubmed/35723868
http://dx.doi.org/10.1007/s40268-022-00391-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433633/
https://www.ncbi.nlm.nih.gov/pubmed/35723868
http://dx.doi.org/10.1007/s40268-022-00391-6

Ejemplares similares